Shattuck Labs reported a narrowed net loss for the fourth quarter of 2025 as it transitioned its focus toward the SL-325 DR3 blocking antibody program. The company significantly reduced R&D expenses following the discontinuation of the SL-172154 program and strengthened its balance sheet through early 2026 capital markets activity, extending its cash runway into 2029.

Shattuck Labs posted no collaboration revenue in Q2 2025 and reported a net loss of $12.5M. R&D and G&A expenses decreased significantly year-over-year. The company ended the quarter with $50.5M in cash and cash equivalents and anticipates that funds from its recent private placement will support operations into 2029.

Shattuck Labs reported a net loss of $13.7 million for Q1 2025, an improvement from the $18.5 million loss in Q1 2024. The company's cash and cash equivalents stood at $60.9 million, expected to fund operations into 2027. Key developments include the advancement of the SL-325 program with an IND filing expected in Q3 2025.

In Q4 2024, Shattuck Labs reported no revenue and a net loss of $18.68 million, or -$0.37 per share. Operating expenses remained stable, with R&D and G&A expenses similar to the previous year. The company held $73 million in cash and investments at quarter-end, expected to fund operations into 2027.

Shattuck Labs reported a net loss of $16.7 million for the quarter ended September 30, 2024, with cash and cash equivalents and investments of $90.1 million. The company is focusing on the development of SL-325 and expects its cash to fund operations into 2027.

Shattuck Labs reported a net loss of $17.7 million for the fourth quarter of 2023, compared to a net loss of $25.4 million for the same period in 2022. The company's cash and cash equivalents and investments were $130.6 million as of December 31, 2023, and are expected to fund operations into 2026.

Shattuck Labs reported fourth quarter revenue of $30.1 million and net income of $7.8 million, or $0.19 per basic share and $0.18 per diluted share. The company's cash, cash equivalents and short-term investments were $268.8 million as of December 31, 2021.

Shattuck Labs reported financial results for the fourth quarter and full year ended December 31, 2020. The company's cash and cash equivalents and short-term investments were $335.4 million as of December 31, 2020, and believes this will be sufficient to fund operations through 2024.